Items where authors include "Din, O"

Article

Brown, JE, Royle, K-L orcid.org/0000-0003-0225-1199, Gregory, W et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Parker, CC, James, ND, Brawley, CD et al. (43 more authors) (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLOS Medicine, 19 (6). e1003998. ISSN 1549-1277

Dearnaley, D, Hinder, V, Hijab, A et al. (26 more authors) (2022) Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial. The Lancet Oncology. ISSN 1470-2045

Parikh, S, Murray, L orcid.org/0000-0003-0658-6455, Kenning, L et al. (10 more authors) (2018) Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer. Clinical Oncology, 30 (9). pp. 548-555. ISSN 0936-6555

Powles, T, Wheater, M, Din, O et al. (11 more authors) (2016) A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. European Urology, 69 (3). pp. 450-456. ISSN 0302-2838

Proceedings Paper

Brown, JE, Royle, K-L orcid.org/0000-0003-0225-1199, Ralph, C et al. (17 more authors) (2021) STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC). In: Annals of Oncology. ESMO Congress 2021, 16-21 Sep 2021, Paris, France. Elsevier , S1303-S1304.